Get started
Author

Luis Paz‐Ares

Practical Considerations for the Use of Circulating Tumor DNA in the Treatment of Patients With Cancer
2022 · Matthew G. Krebs, Umberto Malapelle, et al. · JAMA Oncology · 128
Impact of the COVID-19 outbreak on cancer patient flow and management: experience from a large university hospital in Spain
2020 · Luis Manso, Guillermo De Velasco, et al. · ESMO Open · 127
Clinical and pathological associations of PTEN expression in ovarian cancer: a multicentre study from the Ovarian Tumour Tissue Analysis Consortium
2020 · Filipe Correia Martins, Dominique-Laurent Couturier, et al. · British Journal of Cancer · 65
PDF
MyD88 and TLR4 Expression in Epithelial Ovarian Cancer
2018 · Matthew S. Block, Robert A. Vierkant, et al. · Mayo Clinic Proceedings · 31
PDF
p53 and ovarian carcinoma survival: an Ovarian Tumor Tissue Analysis consortium study
2023 · Martin Köbel, Eun‐Young Kang, et al. · The Journal of Pathology Clinical Research · 30
PDF
The NER-related gene GTF2H5 predicts survival in high-grade serous ovarian cancer patients
2015 · Javier Gayarre, Marta M. Kamieniak, et al. · Journal of Gynecologic Oncology · 29
PDF
Deletion at 6q24.2–26 predicts longer survival of high‐grade serous epithelial ovarian cancer patients
2014 · Marta M. Kamieniak, Daniel Rico, et al. · Molecular Oncology · 29
PDF
Increased FOXJ1 protein expression is associated with improved overall survival in high-grade serous ovarian carcinoma: an Ovarian Tumor Tissue Analysis Consortium Study
2022 · Ashley Weir, Eun-Young Kang, et al. · British Journal of Cancer · 6
PDF
Randomized Study of Cefepime versus Ceftazidime plus Amikacin in Patients with Solid Tumors Treated with High Dose Chemotherapy (HDC) and Peripheral Blood Stem Cell Support (PBSCS) with Febrile Neutropenia
2006 · Antonio Jimeno, Alberto Arcediano, et al. · Clinical & Translational Oncology · 5
Telomere-based risk models for the early diagnosis of lung cancer
2024 · Sonia Molina-Pinelo, Irene Ferrer Sánchez, et al. · Heliyon · 3
Abstract CT248: Zidesamtinib in patients with ROS1+ NSCLC previously treated with repotrectinib or taletrectinib
2026 · Geoffrey Liu, Alexander E. Drilon, et al. · Cancer Research · 2
PP01.59: ABBIL1TY NSCLC-06: A Global, Randomized, Open-Label, Phase 3 Trial of Acasunlimab in Combination with Pembrolizumab vs Docetaxel in Checkpoint Inhibitor–Experienced Patients with PD-L1+ Metastatic Non-Small Cell Lung Cancer
2026 · Luis Paz-Ares, Benjamin Besse, et al. · Journal of Thoracic Oncology · 1
Durvalumab plus platinum-etoposide in the first-line treatment of extensive-stage small cell lung cancer (CANTABRICO): A single-arm clinical trial
2025 · Dolores Isla, Jon Zugazagoitia, et al. · Lung Cancer · 1
PDF
756 A phase 2 trial of the IO102-IO103 cancer vaccine plus pembrolizumab: results from the first-line (1L) cohort of PD-L1 high metastatic non-small cell lung cancer (NSCLC)
2024 · Jonathan W Riess, James Spicer, et al. · Regular and Young Investigator Award Abstracts · 1
Vibostolimab Coformulated with Pembrolizumab Plus Chemotherapy as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer
2026 · Jacob Sands, Shun Lu, et al. · Targeted Oncology
PDF
Intensive Care in Patients with Solid Tumours: A Practical Framework for Integrated Onco-Critical Care
2026 · Alicia Castelo-Loureiro, Amanda Lesmes González de Aledo, et al. · Cancers
Context-dependent value of HLA class I diversity in advanced non-small cell lung cancer treated with immune checkpoint blockade
2026 · Javier Ramos-Paradas, Nuria Carrizo, et al. · Frontiers in Immunology
PDF
PP01.144: Patient-Reported Outcomes (PROs) from IMforte: A Phase 3 Study of First-Line Maintenance Treatment with Lurbinectedin + Atezolizumab Versus Atezolizumab in Patients with Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
2026 · Roy S. Herbst, Luis Paz-Ares, et al. · Journal of Thoracic Oncology
PP01.118: Phase 1b/2 trial of BNT324/DB-1311 (B7H3 ADC) with Pumitamig (BNT327; PD-L1 x VEGF-A bsAb) in Lung Cancer (SCLC or NSCLC): BNT324-01 Trial in Progress
2026 · Adam Schoenfeld, Alexander Spira, et al. · Journal of Thoracic Oncology
PP01.56: Final, 6-Year Outcomes with First-Line (1L) Nivolumab Plus Ipilimumab Plus Chemotherapy (N+I+C) in Patients with Metastatic Non-Small Cell Lung Cancer (mNSCLC) from CheckMate 9LA
2026 · Firas B. Badin, David P. Carbone, et al. · Journal of Thoracic Oncology
Abstract CT193: Intracranial activity of ZL-1310, a DLL3-targeted ADC, in patients with previously treated extensive-stage small cell lung cancer and baseline brain metastasis: Analysis of a phase 1 trial
2026 · Pedro Rocha, Manish Patel, et al. · Cancer Research
Abstract LB418: RELATIVITY-104 Part 2: translational analyses in the programmed death ligand 1 (PD-L1) ≥ 1% and non-squamous (NSQ) non-small cell lung cancer (NSCLC) subgroup
2026 · Jaclyn Neely, Annie Yu, et al. · Cancer Research
A video summary of the DeLLphi-301 study: tarlatamab as a treatment option for small cell lung cancer
2026 · Myung-Ju Ahn, Byoung Chul Cho, et al. · Video Journal of Biomedicine
Real-World Data of First-Line Cemiplimab Monotherapy for Metastatic Non-Small Cell Lung Cancer (NSCLC) with PD-L1 Expression ≥ 50%: A National Spanish Multicentric Cohort (CEMI-SPA Study)
2025 · Silvia Masini, Monica Antoñanzas Basa, et al. · Cancers
PDF
Optoplasmonisc biosensor for ultrasensitive detection of interleukin 11 (IL-11): towards single-cell analysis in lung cancer
2025 · Lázaro, Víctor, García-López, Sergio, et al. · DIGITAL.CSIC (Spanish National Research Council (CSIC))
PDF
Works count: 30
Citation count: 458
H-index: 7
I10-index: 7
Year
Topic
Type